Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
Metadata
Show full item recordAuthor
Delgado Ureña, Mayte; Ortega, Francisco G.; Miguel-Pérez, Diego de; Rodríguez Martínez, Alba; García Puche, José Luis; Ilyine, Hugh; Lorente Acosta, José Antonio; Expósito Hernández, José; Garrido Navas, María del Carmen; Delgado Ramírez, Miguel; Serrano, M. JoseEditorial
Springer Nature
Materia
Metastatic colorectal cancer Bevacizumab Circulating tumor cells RECIST CyCAR Prognosis
Date
2018Referencia bibliográfica
Delgado-Ureña, M., Ortega, F. G., de Miguel-Pérez, D., Rodriguez-Martínez, A., García-Puche, J. L., Ilyine, H., ... & Serrano, M. J. (2018). Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. Journal of translational medicine, 16(1), 251.
Sponsorship
This work was supported by Roche Spain and a Ph.D. grant from the University of Granada.Abstract
The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal
cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid
Tumors (RECIST) with the Cytologic Criteria Assessing Response (CyCAR), based on the presence and phenotypic
characterization of CTCs, as indicators of FOLFOX–bevacizumab treatment response. We observed a decrease of CTCs (42.8 vs. 18.2%) and VEGFR positivity (69.7% vs. 41.7%) after treatment.
According to RECIST, 6.45% of the patients did not show any clinical benefit, whereas 93.55% patients showed a
favorable response at 12 weeks. According to CyCAR, 29% had a non-favorable response and 71% patients did not. No
significant differences were found between the response assessment by RECIST and CyCAR at 12 or 24 weeks. However,
in the multivariate analysis, RECIST at 12 weeks and CyCAR at 24 weeks were independent prognostic factors for
OS (HR: 0.1, 95% CI 0.02–0.58 and HR: 0.35, 95% CI 0.12–0.99 respectively). CyCAR results were comparable to RECIST in evaluating the response in mCRC and can be used as an
alternative when the limitation of RECIST requires additional response analysis techniques.